DE69832730D1 - Methode zur behandlung von dopaminergen und gaba-nergen störungen - Google Patents
Methode zur behandlung von dopaminergen und gaba-nergen störungenInfo
- Publication number
- DE69832730D1 DE69832730D1 DE69832730T DE69832730T DE69832730D1 DE 69832730 D1 DE69832730 D1 DE 69832730D1 DE 69832730 T DE69832730 T DE 69832730T DE 69832730 T DE69832730 T DE 69832730T DE 69832730 D1 DE69832730 D1 DE 69832730D1
- Authority
- DE
- Germany
- Prior art keywords
- gaba
- hedgehog
- nergenic
- dopaminergen
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000289669 Erinaceus europaeus Species 0.000 abstract 2
- 210000005064 dopaminergic neuron Anatomy 0.000 abstract 2
- 210000001259 mesencephalon Anatomy 0.000 abstract 2
- 102000003693 Hedgehog Proteins Human genes 0.000 abstract 1
- 108090000031 Hedgehog Proteins Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000001228 trophic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US900220 | 1997-07-24 | ||
US08/900,220 US7144997B2 (en) | 1997-07-24 | 1997-07-24 | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto |
PCT/US1998/015419 WO1999004775A2 (en) | 1997-07-24 | 1998-07-24 | Method of treating dopaminergic and gaba-nergic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69832730D1 true DE69832730D1 (de) | 2006-01-12 |
DE69832730T2 DE69832730T2 (de) | 2006-08-17 |
Family
ID=25412184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69832730T Expired - Fee Related DE69832730T2 (de) | 1997-07-24 | 1998-07-24 | Methode zur behandlung von dopaminergen und gaba-nergen störungen |
Country Status (10)
Country | Link |
---|---|
US (3) | US7144997B2 (de) |
EP (2) | EP1723950A2 (de) |
JP (1) | JP2001510796A (de) |
AT (1) | ATE311863T1 (de) |
AU (1) | AU8589398A (de) |
CA (1) | CA2297410A1 (de) |
DE (1) | DE69832730T2 (de) |
DK (1) | DK1067917T3 (de) |
ES (1) | ES2253822T3 (de) |
WO (1) | WO1999004775A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH114695A (ja) * | 1997-04-25 | 1999-01-12 | Hayashibara Biochem Lab Inc | ヘッジホッグ蛋白質 |
AU8173098A (en) | 1997-06-27 | 1999-01-19 | Ontogeny, Inc. | Neuroprotective methods and reagents |
US7144997B2 (en) | 1997-07-24 | 2006-12-05 | Curis, Inc. | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto |
US6639051B2 (en) | 1997-10-20 | 2003-10-28 | Curis, Inc. | Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
AU1716599A (en) | 1997-12-08 | 1999-06-28 | Curis, Inc. | Human patched genes and proteins, and uses related thereto |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6884770B1 (en) | 1998-11-06 | 2005-04-26 | Curis, Inc. | Methods and compositions for treating or preventing peripheral neuropathies |
US20030083242A1 (en) * | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
US20050042749A1 (en) | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
WO2001088104A2 (en) | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
JP2002348239A (ja) * | 2000-10-05 | 2002-12-04 | Takeda Chem Ind Ltd | 幹細胞・神経前駆細胞の増殖・分化促進剤 |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20040014956A1 (en) | 2002-02-01 | 2004-01-22 | Sequitur, Inc. | Double-stranded oligonucleotides |
EP1670901A4 (de) * | 2003-08-29 | 2007-09-05 | Wisconsin Alumni Res Found | Verfahren zur in-vitro-differenzierung von neuralen stammzellen, motorneuronen und dopaminneuronen aus embryonalen primatenstammzellen |
MXPA06006659A (es) * | 2003-12-19 | 2006-08-31 | Curis Inc | Composicion y metodos para modular la actividad del sistema nervioso central. |
WO2006020996A2 (en) | 2004-08-11 | 2006-02-23 | Cedars-Sinai Medical Center | Treatment of parkinson's disease and related disorders |
US7858590B2 (en) | 2005-08-11 | 2010-12-28 | Cedars-Sinai Medical Center | Treatment of parkinson's disease and related disorders |
US10160950B2 (en) | 2013-03-01 | 2018-12-25 | Wisconsin Alumni Research Foundation | Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors |
US20140248696A1 (en) * | 2013-03-01 | 2014-09-04 | Wisconsin Alumni Research Foundation | Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors |
WO2018129421A1 (en) * | 2017-01-09 | 2018-07-12 | Genervon Biopharmaceuticals, LLC | A promising drug candidate for parkinson's disease |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456687A (en) | 1978-11-16 | 1984-06-26 | President And Fellows Of Harvard College | Agents for promoting growth of epithelial cells |
EP0187371B1 (de) | 1984-12-27 | 1991-06-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Substituierte Isochinolinsulfonyl-Verbindungen |
DE3786714T2 (de) | 1986-06-16 | 1994-03-10 | Daiichi Seiyaku Co | Therapeutisches Mittel für Hautgeschwüre. |
JPH0745383B2 (ja) | 1986-09-30 | 1995-05-17 | 第一製薬株式会社 | 環状アデノシン誘導体含有毛髪用剤 |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
DE3942114C2 (de) | 1988-12-26 | 1997-09-04 | Hiroyoshi Hidaka | Verbindungen mit einer Wirkung für eine gleichmäßige Gefäßmuskelentspannung und pharmazeutische Zusammensetzung, die diese enthält |
EP0464206A4 (en) | 1989-03-24 | 1992-05-13 | Daiichi Pharmaceutical Co., Ltd. | Drug for improving brain function |
JPH02273610A (ja) | 1989-04-17 | 1990-11-08 | Chugai Pharmaceut Co Ltd | 発毛促進剤 |
JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
JPH04305528A (ja) | 1991-02-22 | 1992-10-28 | Dai Ichi Seiyaku Co Ltd | ケラチノサイト及び皮膚線維芽細胞の増殖刺激剤 |
EP0575485A1 (de) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Verfahren zur entwicklung bindender miniproteine |
US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
JPH07505124A (ja) | 1991-11-08 | 1995-06-08 | ザ ユニバーシティ オブ サザン カリフォルニア | ニューロトロフィン活性増強のためのk−252化合物を含む組成物 |
US5461146A (en) | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
JP2893029B2 (ja) | 1992-08-10 | 1999-05-17 | 旭化成工業株式会社 | 心臓保護剤 |
US6333168B1 (en) | 1993-05-20 | 2001-12-25 | The Trustees Of Columbia University In The City Of New York | Cloning, expression and uses of dorsalin-1 |
US5519035A (en) | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
US6610656B1 (en) * | 1993-12-30 | 2003-08-26 | President And Fellows Of Harvard College | Method of promoting chondrocyte differentiation with hedgehog related polypeptides |
US5789543A (en) | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
US20030186357A1 (en) * | 1993-12-30 | 2003-10-02 | Philip W. Ingham | Vertebrate embryonic pattern-inducing proteins, and uses related thereto |
CA2179029C (en) | 1993-12-30 | 2009-02-24 | Philip W. Ingham | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
US6884775B1 (en) * | 1993-12-30 | 2005-04-26 | President And Fellows Of Harvard College | Methods and compositions for regulating skeletogenic formation |
US7060450B1 (en) * | 1993-12-30 | 2006-06-13 | President And Fellows Of Harvard College | Screening assays for agonists and antagonists of the hedgehog signaling pathway |
US6165747A (en) * | 1993-12-30 | 2000-12-26 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
US6261786B1 (en) * | 1993-12-30 | 2001-07-17 | Imperial Cancer Res. Technology | Screening assays for hedgehog agonists and antagonists |
US6271363B1 (en) * | 1993-12-30 | 2001-08-07 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
EP0773995A4 (de) | 1994-02-25 | 1997-07-16 | Univ Columbia | Dna kodierend für das wirbeltier-homologe des hedgehog, vhh-1, exprimiert in notochord und seine verwendung |
US5585087A (en) | 1994-06-08 | 1996-12-17 | President And Fellows Of Harvard College | Assay for identifying extracellular signaling proteins |
US5554608A (en) | 1994-09-28 | 1996-09-10 | Ahluwalia; Gurpreet S. | Inhibition of hair growth |
US6429354B1 (en) * | 1994-10-07 | 2002-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Patched genes and uses related thereto |
EP0804548B1 (de) * | 1994-10-07 | 2005-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ptc gene und ihre verwendung |
US6946257B1 (en) * | 1994-10-07 | 2005-09-20 | Regents Of The University Of California | Patched genes and uses related thereto |
US6027882A (en) | 1994-10-07 | 2000-02-22 | The Regents Of The University Of California | Patched genes and their use for diagnostics |
US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
WO1997011095A1 (en) | 1995-09-21 | 1997-03-27 | The Trustees Of Columbia University In The City Of New York | Uses of bone morphogenetic proteins |
ATE335819T1 (de) | 1996-09-20 | 2006-09-15 | Harvard College | Hedgehog wechselwirkende proteine und ihre darauf bezogenen anwendungen |
US5990281A (en) | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
IL129295A0 (en) | 1996-10-07 | 2000-02-17 | Univ Johns Hopkins Med | Novel hedgehog-derived polypeptides |
US5759811A (en) | 1996-11-13 | 1998-06-02 | The Regents Of The University Of California | Mutant human hedgehog gene |
JPH10194987A (ja) | 1997-01-14 | 1998-07-28 | Youtai Iwamoto | 骨・軟骨形成用組成物 |
JP4669968B2 (ja) | 1997-02-10 | 2011-04-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 造血及び血管生成の調節方法 |
JPH114695A (ja) | 1997-04-25 | 1999-01-12 | Hayashibara Biochem Lab Inc | ヘッジホッグ蛋白質 |
EP0879888A3 (de) | 1997-05-23 | 1999-07-14 | Smithkline Beecham Plc | Patched-2 Polypeptide und Polynucleotide und Methoden zu ihrer Herstellung |
AU8173098A (en) * | 1997-06-27 | 1999-01-19 | Ontogeny, Inc. | Neuroprotective methods and reagents |
US6218144B1 (en) | 1997-06-30 | 2001-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Costal2 genes and their uses |
WO1999001468A2 (en) | 1997-07-01 | 1999-01-14 | Ontogeny, Inc. | Vertebrate smoothened gene, gene products, and uses related thereto |
US7144997B2 (en) | 1997-07-24 | 2006-12-05 | Curis, Inc. | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto |
WO1999010004A2 (en) | 1997-08-29 | 1999-03-04 | Ontogeny, Inc. | Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto |
US20020026043A1 (en) | 1998-02-06 | 2002-02-28 | Brian Taylor Edmonds | Desert hedgehog related nucleic acids and proteins |
-
1997
- 1997-07-24 US US08/900,220 patent/US7144997B2/en not_active Expired - Fee Related
-
1998
- 1998-07-24 DK DK98937104T patent/DK1067917T3/da active
- 1998-07-24 WO PCT/US1998/015419 patent/WO1999004775A2/en active IP Right Grant
- 1998-07-24 AU AU85893/98A patent/AU8589398A/en not_active Abandoned
- 1998-07-24 EP EP05026453A patent/EP1723950A2/de not_active Withdrawn
- 1998-07-24 CA CA002297410A patent/CA2297410A1/en not_active Abandoned
- 1998-07-24 ES ES98937104T patent/ES2253822T3/es not_active Expired - Lifetime
- 1998-07-24 JP JP2000503834A patent/JP2001510796A/ja active Pending
- 1998-07-24 DE DE69832730T patent/DE69832730T2/de not_active Expired - Fee Related
- 1998-07-24 AT AT98937104T patent/ATE311863T1/de not_active IP Right Cessation
- 1998-07-24 EP EP98937104A patent/EP1067917B1/de not_active Expired - Lifetime
-
1999
- 1999-12-01 US US09/451,939 patent/US7138492B2/en not_active Expired - Fee Related
-
2006
- 2006-10-25 US US11/586,768 patent/US20070048286A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070048286A1 (en) | 2007-03-01 |
WO1999004775A3 (en) | 2000-11-23 |
US7144997B2 (en) | 2006-12-05 |
JP2001510796A (ja) | 2001-08-07 |
US7138492B2 (en) | 2006-11-21 |
US20020045206A1 (en) | 2002-04-18 |
WO1999004775A9 (en) | 1999-04-29 |
EP1067917B1 (de) | 2005-12-07 |
EP1723950A2 (de) | 2006-11-22 |
EP1067917A2 (de) | 2001-01-17 |
ES2253822T3 (es) | 2006-06-01 |
DK1067917T3 (da) | 2006-04-18 |
AU8589398A (en) | 1999-02-16 |
ATE311863T1 (de) | 2005-12-15 |
WO1999004775A2 (en) | 1999-02-04 |
DE69832730T2 (de) | 2006-08-17 |
US20030119729A1 (en) | 2003-06-26 |
CA2297410A1 (en) | 1999-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69832730D1 (de) | Methode zur behandlung von dopaminergen und gaba-nergen störungen | |
DE69839014D1 (de) | Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen | |
DE69829412D1 (de) | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen | |
DE3779149D1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
DE69836752D1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
DE58902094D1 (de) | Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen. | |
DE3687069D1 (de) | Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen. | |
DE69830513D1 (de) | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN | |
DE3886254D1 (de) | Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat. | |
ATE236529T1 (de) | Antiparasitäre zusammensetzung zur behandlung und zum schutz von haustieren | |
DE3579113D1 (de) | Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden. | |
DE69736862D1 (de) | System zur genetischen behandlung von stoerungen der herzleistung | |
DE69435038D1 (de) | Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie | |
DE69840752D1 (de) | Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen | |
ATE95064T1 (de) | Verwendung von angiotensin-converting-enzyminhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit. | |
ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
DE69727240D1 (de) | Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
DE69729735D1 (de) | Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen | |
DE3852625D1 (de) | Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C. | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
DE69931390D1 (de) | Verfahren unfd zusammensetzungen zur behandlung von krankheiten bei denen exitotoxizität beteiligt ist | |
ATA412084A (de) | Vorrichtung zur kultivierung und behandlung von biokatalysatoren | |
DE3787954D1 (de) | Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen. | |
DE60016183D1 (de) | Verfahren zur verwendung von viraler replicase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |